Ryan Kohlbrenner
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ryan Kohlbrenner has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
Nicholas Fidelman
Department of Radiology and Biomedical Imaging, University of California, San Francisco, 505 Parnassus Ave., M-361, San Francisco, CA 94143
4 shared publications- Andrew G. Taylor
University of California San Francisco
3 shared publications K. Pallav Kolli
Department of Radiology and Biomedical Imaging, University of California, San Francisco, 505 Parnassus Ave., M-361, San Francisco, CA 94143
3 shared publicationsMaureen P. Kohi
Department of Radiology and Biomedical Imaging, University of California, San Francisco, 505 Parnassus Ave., M-361, San Francisco, CA 94143
3 shared publicationsMiles Conrad
University of California - San Francisco, San Francisco, USA
3 shared publications- Adam Schwertner
Department of Radiology, Denver Health Medical Center, 777 Bannock Street, MC 0024, Denver CO, 80204, United States; The University of Colorado School of Medicine, Department of Radiology, 12401 East 17(th) Avenue, Aurora CO, 80045, United States
2 shared publications
Latest Publications
- Open Access
- 18 November 2025
- Published by Springer Nature in CardioVascular and Interventional Radiology
- Vol. 49 (2) , 313-321
Cryoablation Versus Breast-Conserving Surgery for Early-Stage, Low-Risk Breast Cancer ≤ 1.5 cm: A Cost-Effectiveness Analysis
Purpose: To compare ultrasound-guided cryoablation (BCA) and breast-conserving surgery (BCS) for patients with early-stage, low-risk breast cancer using a cost-effectiveness analysis. Materials and Methods: A Markov decision tree was constructed comparing BCA and BCS for unifocal small (≤ 1.5 cm), lymph node-negative, ultrasound-visible breast cancer from a payer’s perspective over a 5-year horizon. Clinical outcomes after cryoablation were based on the ICE3 trial, and those after BCS were based on a meta-analysis of 17 trials. Outcomes were measured in US dollars and quality-adjusted life years (QALY). Base case calculation, probabilistic and deterministic sensitivity analyses were performed. Results: Base case analysis showed BCA achieved comparable health outcomes (0.01–0.09 QALY higher) at a lower cost (at least $17,682 of cost saving per patient). Probabilistic sensitivity analysis showed cryoablation to be the better strategy in majority of the iterations driven by its lower procedural cost. BCS became the better strategy when the annual mortality after BCA was > 2.1%, equivalent to a 5-year cancer survival after BCA < 90.0%. BCA was the more optimal strategy when its annual local recurrence risk was < 51.5% or distant recurrence risk was < 1.04%. BCS became the more cost-effective strategy if the cost of BCA was $20,906 more than BCS. BCA remained more cost-effective when accounting for follow-up, provided the difference in costs between BCA and BCS was less than $4000 annually. Conclusion: BCA is a cost-effective strategy for patients with early-stage, low-risk, sonographically visible breast cancer when compared to BCS. Graphical
- 18 November 2025
- Published by Springer Nature in CardioVascular and Interventional Radiology
- Vol. 49 (2) , 313-321
Open AccessCryoablation Versus Breast-Conserving Surgery for Early-Stage, Low-Risk Breast Cancer ≤ 1.5 cm: A Cost-Effectiveness Analysis
Purpose: To compare ultrasound-guided cryoablation (BCA) and breast-conserving surgery (BCS) for patients with early-stage, low-risk breast cancer using a cost-effectiveness analysis. Materials and Methods: A Markov decision tree was constructed comparing BCA and BCS for unifocal small (≤ 1.5 cm), lymph node-negative, ultrasound-visible breast cancer from a payer’s perspective over a 5-year horizon. Clinical outcomes after cryoablation were based on the ICE3 trial, and those after BCS were based on a meta-analysis of 17 trials. Outcomes were measured in US dollars and quality-adjusted life years (QALY). Base case calculation, probabilistic and deterministic sensitivity analyses were performed. Results: Base case analysis showed BCA achieved comparable health outcomes (0.01–0.09 QALY higher) at a lower cost (at least $17,682 of cost saving per patient). Probabilistic sensitivity analysis showed cryoablation to be the better strategy in majority of the iterations driven by its lower procedural cost. BCS became the better strategy when the annual mortality after BCA was > 2.1%, equivalent to a 5-year cancer survival after BCA < 90.0%. BCA was the more optimal strategy when its annual local recurrence risk was < 51.5% or distant recurrence risk was < 1.04%. BCS became the more cost-effective strategy if the cost of BCA was $20,906 more than BCS. BCA remained more cost-effective when accounting for follow-up, provided the difference in costs between BCA and BCS was less than $4000 annually. Conclusion: BCA is a cost-effective strategy for patients with early-stage, low-risk, sonographically visible breast cancer when compared to BCS. Graphical
- 22 January 2025
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 36 (2) , 371
Embolization of diffuse idiopathic pulmonary neuroendocrine cell hyperplasia
- 22 January 2025
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 36 (2) , 371
Embolization of diffuse idiopathic pulmonary neuroendocrine cell hyperplasia
- 1 August 2024
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 312 (2) , e232544
Pharmacokinetic Comparison of Selective Prostatic Arterial and Intravenous PSMA PET/CT Radioligand Infusions in Primary Prostatic Adenocarcinoma
Selective prostatic arterial infusion yielded higher radiotracer uptake in prostatic tumors than intravenous infusions when using dynamic prostate-specific membrane antigen PET/CT to simulate radioligand therapy.
- 1 August 2024
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 312 (2) , e232544
Pharmacokinetic Comparison of Selective Prostatic Arterial and Intravenous PSMA PET/CT Radioligand Infusions in Primary Prostatic Adenocarcinoma
Selective prostatic arterial infusion yielded higher radiotracer uptake in prostatic tumors than intravenous infusions when using dynamic prostate-specific membrane antigen PET/CT to simulate radioligand therapy.
- 1 December 2023
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 309 (3) , e230555
Comparison of Minimally Invasive Procedures for Benign Prostatic Hyperplasia: A Cost-effectiveness Analysis
Background Benign prostatic hyperplasia (BPH) is a disease that affects millions of U.S. men and is costly to treat. Purpose To compare the cost-effectiveness of four minimally invasive therapies (MITs) and medical management for the treatment of BPH. Materials and Methods A cost-effectiveness analysis from a payer's perspective with Markov modeling was performed, comparing prostatic artery embolization (PAE), prostatic urethral lift, aquablation, water vapor thermal therapy, and medical management for BPH spanning a time horizon of 5 years. The model incorporated the probability of procedural complications and recurrent symptoms necessitating retreatment, which were extracted from published studies with long-term follow-up. Costs were based on Medicare reimbursements using CPT codes for ambulatory surgery centers. Outcomes were measured using the quality-adjusted life year (QALY), incorporating both life quality and expectancy. Statistical analyses included a base case calculation (using the most probable value of each parameter) and probabilistic and deterministic sensitivity analyses. Results In the base case calculation, outcomes for the strategies were comparable, with a difference of 0.030 QALY (11 days of life in perfect health) between the most (PAE) and least (medical management) effective strategies. PAE was the most cost-effective strategy relative to medical management, with an incremental cost-effectiveness ratio of $64 842 per QALY. Probabilistic sensitivity analysis showed PAE was more cost-effective compared with prostatic urethral lift, aquablation, water vapor therapy, and medical management in pairwise comparisons. In sensitivity analysis of retreatment risk, PAE remained the most cost-effective strategy until its repeat treatment rates exceeded 2.30% per 6 months, at which point water vapor therapy became the optimal choice. PAE was the most cost-effective procedure when its procedural cost was lower than $4755. Aquablation and prostatic urethral lift became more cost-effective when their procedural costs were lower than $3015 and $1097, respectively. Conclusion This modeling-based study showed that PAE appears to be a cost-effective modality among medical management and MITs for patients with BPH, with comparable outcomes to prostatic urethral lift, water vapor therapy, and aquablation at a lower expected cost. © RSNA, 2023 Supplemental material is available for this article. See also the editorial by Gemmete in this issue.
- 1 December 2023
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 309 (3) , e230555
Comparison of Minimally Invasive Procedures for Benign Prostatic Hyperplasia: A Cost-effectiveness Analysis
Background Benign prostatic hyperplasia (BPH) is a disease that affects millions of U.S. men and is costly to treat. Purpose To compare the cost-effectiveness of four minimally invasive therapies (MITs) and medical management for the treatment of BPH. Materials and Methods A cost-effectiveness analysis from a payer's perspective with Markov modeling was performed, comparing prostatic artery embolization (PAE), prostatic urethral lift, aquablation, water vapor thermal therapy, and medical management for BPH spanning a time horizon of 5 years. The model incorporated the probability of procedural complications and recurrent symptoms necessitating retreatment, which were extracted from published studies with long-term follow-up. Costs were based on Medicare reimbursements using CPT codes for ambulatory surgery centers. Outcomes were measured using the quality-adjusted life year (QALY), incorporating both life quality and expectancy. Statistical analyses included a base case calculation (using the most probable value of each parameter) and probabilistic and deterministic sensitivity analyses. Results In the base case calculation, outcomes for the strategies were comparable, with a difference of 0.030 QALY (11 days of life in perfect health) between the most (PAE) and least (medical management) effective strategies. PAE was the most cost-effective strategy relative to medical management, with an incremental cost-effectiveness ratio of $64 842 per QALY. Probabilistic sensitivity analysis showed PAE was more cost-effective compared with prostatic urethral lift, aquablation, water vapor therapy, and medical management in pairwise comparisons. In sensitivity analysis of retreatment risk, PAE remained the most cost-effective strategy until its repeat treatment rates exceeded 2.30% per 6 months, at which point water vapor therapy became the optimal choice. PAE was the most cost-effective procedure when its procedural cost was lower than $4755. Aquablation and prostatic urethral lift became more cost-effective when their procedural costs were lower than $3015 and $1097, respectively. Conclusion This modeling-based study showed that PAE appears to be a cost-effective modality among medical management and MITs for patients with BPH, with comparable outcomes to prostatic urethral lift, water vapor therapy, and aquablation at a lower expected cost. © RSNA, 2023 Supplemental material is available for this article. See also the editorial by Gemmete in this issue.
- 12 August 2022
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 33 (12) , 1605-1615
Prostatic Artery Embolization Versus Transurethral Resection of the Prostate for Benign Prostatic Hyperplasia: A Cost-Effectiveness Analysis
- 12 August 2022
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 33 (12) , 1605-1615
Prostatic Artery Embolization Versus Transurethral Resection of the Prostate for Benign Prostatic Hyperplasia: A Cost-Effectiveness Analysis
- Open Access
- 8 February 2022
- Published by Springer Nature in CVIR Endovascular
- Vol. 5 (1) , 1-6
Large thrombosed portomesenteric venous aneurysm treated with pharmacomechanical thrombolysis combined with TIPS placement
Aneurysms are rare anomalies of the portomesenteric venous system. Thrombotic complications of these lesions can lead to mesenteric venous ischemia and bowel infarction, potentially requiring surgical intervention. Herein we describe a case of mesenteric ischemia due to a large thrombosed portomesenteric aneurysm treated with endovascular techniques. A 37-year-old previously healthy male who presented with abdominal pain to his local emergency department was found to have a thrombosed 12.0 × 5.1 cm portomesenteric venous aneurysm with evidence of mesenteric ischemia on CT. When conservative management with anticoagulation failed, transhepatic pharmacomechanical thrombolysis was initially performed. This was followed by TIPS placement with additional trans-TIPS thrombectomy to improve sluggish portal outflow and prevent re-thrombosis. The patient’s symptoms and imaging findings of ischemia resolved after endovascular therapy. No surgical intervention was required, and the patient was discharged on enoxaparin before being transitioned to apixaban. The TIPS remained patent at 2-year follow-up, with no change in the size of the aneurysm or re-thrombosis noted. The patient’s synthetic liver function was preserved with no evidence of hepatic encephalopathy during the follow-up period. Endovascular therapies may be used to manage thrombotic complications of portomesenteric venous aneurysms, obviating the need for surgical intervention in selected patients.
- 8 February 2022
- Published by Springer Nature in CVIR Endovascular
- Vol. 5 (1) , 1-6
Open AccessLarge thrombosed portomesenteric venous aneurysm treated with pharmacomechanical thrombolysis combined with TIPS placement
Aneurysms are rare anomalies of the portomesenteric venous system. Thrombotic complications of these lesions can lead to mesenteric venous ischemia and bowel infarction, potentially requiring surgical intervention. Herein we describe a case of mesenteric ischemia due to a large thrombosed portomesenteric aneurysm treated with endovascular techniques. A 37-year-old previously healthy male who presented with abdominal pain to his local emergency department was found to have a thrombosed 12.0 × 5.1 cm portomesenteric venous aneurysm with evidence of mesenteric ischemia on CT. When conservative management with anticoagulation failed, transhepatic pharmacomechanical thrombolysis was initially performed. This was followed by TIPS placement with additional trans-TIPS thrombectomy to improve sluggish portal outflow and prevent re-thrombosis. The patient’s symptoms and imaging findings of ischemia resolved after endovascular therapy. No surgical intervention was required, and the patient was discharged on enoxaparin before being transitioned to apixaban. The TIPS remained patent at 2-year follow-up, with no change in the size of the aneurysm or re-thrombosis noted. The patient’s synthetic liver function was preserved with no evidence of hepatic encephalopathy during the follow-up period. Endovascular therapies may be used to manage thrombotic complications of portomesenteric venous aneurysms, obviating the need for surgical intervention in selected patients.
- Open Access
- 1 June 2021
- Published by Elsevier in Interdisciplinary Neurosurgery
- Vol. 24
Intracranial hemorrhage due to central venous occlusion from hemodialysis access: A case report
- 1 June 2021
- Published by Elsevier in Interdisciplinary Neurosurgery
- Vol. 24
Open AccessIntracranial hemorrhage due to central venous occlusion from hemodialysis access: A case report
- 7 May 2021
- Published by Galenos Yayinevi in Diagnostic and Interventional Radiology
- Vol. 27 (3) , 458-459
Onyx embolization of an enlarging arterioportal pancreatic AVM using a balloon-occlusion microcatheter
- 7 May 2021
- Published by Galenos Yayinevi in Diagnostic and Interventional Radiology
- Vol. 27 (3) , 458-459
Onyx embolization of an enlarging arterioportal pancreatic AVM using a balloon-occlusion microcatheter
- 1 April 2021
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 32 (4) , 626-628
Nonfibered Packing Coil Embolization of Pulmonary Artery Pseudoaneurysm Resulting in a Delayed Endobronchial Coil Migration
- 1 April 2021
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 32 (4) , 626-628
Nonfibered Packing Coil Embolization of Pulmonary Artery Pseudoaneurysm Resulting in a Delayed Endobronchial Coil Migration
- 1 June 2019
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 30 (6) , 918-921
Outcomes after Peripancreatic Fluid Drainage in Patients with Simultaneous Pancreas-Kidney Transplantation
- 1 June 2019
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 30 (6) , 918-921
Outcomes after Peripancreatic Fluid Drainage in Patients with Simultaneous Pancreas-Kidney Transplantation